Irlanda - engleză - HPRA (Health Products Regulatory Authority)

hospira uk limited - dopamine hydrochloride - concentrate for soln for inf - 40 mg/ml - adrenergic and dopaminergic agents

Malta - engleză - Medicines Authority

hospira uk limited - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg/ml - cardiac therapy

Regatul Unit - engleză - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - dopamine hydrochloride - solution for infusion - 40mg/1ml

Regatul Unit - engleză - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - dopamine hydrochloride - solution for infusion - 40mg/1ml

Regatul Unit - engleză - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - dopamine hydrochloride - solution for infusion - 160mg/1ml

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - dopamine hydrochloride - concentrate for solution for infusion - 40 milligram(s)/millilitre - adrenergic and dopaminergic agents; dopamine

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

ain medicare sdn. bhd. - dopamine hydrochloride -

Malta - engleză - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg/ml - cardiac therapy

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bpi labs, llc - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine injection usp, 1 mg/ml is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. none risk summary prolonged experience with epinephrine use in pregnant women over several decades, based on published literature, does not identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. however, there are risks to the mother and fetus associated with epinephrine use during labor or delivery (see clinical considerations ). in animal reproduction studies, epinephrine administered by the subcutaneous route to pregnant rabbits, mice, and hamsters, during the period of organogenesis, resulted in adverse developmental effects (including gastroschisis, embryonic lethality, and delayed skeletal ossification) at doses approximately 2 times the maximum recommended daily intramuscular, subcutaneous, or intravenous dose (see data ). the estimated background risk of major birth defects and miscarriage